# Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

> **NCT03856853** · PHASE3 · UNKNOWN · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)

## Interventions

- **DRUG:** Pirfenidone
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT03856853
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-15
- **Primary completion:** 2021-02-10
- **Final completion:** 2021-05-10
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856853, "Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03856853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*